Skip to main content

Table 2 Efficacy results in asthma patients at baseline and after treatment with budesonide

From: YKL-40 is correlated with FEV1 and the asthma control test (ACT) in asthmatic patients: influence of treatment

Variable ≤400 μg budesonide per day (n=50) >400 μg budesonide per day (n=31)
  Baseline Visit 2 Baseline Visit 2
FEV1, % predicted 90.8 (0.8) 91.2 (0.6) 71.6 (2.3)* 82.0 (1.8)
ACT score 21.3 (0.7) 22.4 (0.5) 19.1 (0.6)§ 22.5 (0.4)
YKL-40, ng/ml 59.1 (54.3-86.6) 47.5 (40.3-55.3) 86.2 (56.4-96.7)* 55.7 (43.8-63.7)
  1. Data are presented as mean ± SEM, except for YKL-40, median (IQR).
  2. p < 0.001 vs. baseline.
  3. §p < 0.001 vs. baseline (≤400 μg budesonide per day).
  4. *p < 0.01 vs. baseline (≤400 μg budesonide per day).